# Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

> **NCT02765490** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 365 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** AL-335
- **DRUG:** Odalasvir
- **DRUG:** Simeprevir

## Key facts

- **NCT ID:** NCT02765490
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-09
- **Primary completion:** 2017-08-09
- **Final completion:** 2017-11-16
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02765490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02765490, "Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02765490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*